Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat plus Avelumab in Advanced Epithelial Ovarian Cancer
NCT02915523Phase 2Completed
- Sponsor
- Syndax Pharmaceuticals
- Start
- Dec 2016
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Entinostat + Avelumab with Placebo + Avelumab (2 arms). Primary endpoints: Progression Free Survival and Dose Limiting Toxicity. Started Dec 2016; status: completed.
02
Drugs
entinostat
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02915523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02915523.